Michael G McDonell1, Emily Leickly1, Sterling McPherson1, Jordan Skalisky1, Debra Srebnik1, Frank Angelo1, Roger Vilardaga1, Jenny R Nepom1, John M Roll1, Richard K Ries1. 1. From the Initiative for Research and Education to Advance Community Health, Washington State University, Spokane, Wash.; the Elson S. Floyd College of Medicine, Washington State University, Spokane, Wash.; the Program for Excellence in Addiction Research, Washington State University, Spokane, Wash.; the Providence Medical Research Center, Providence Health Care, Spokane, Wash.; the Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Wash.; and the School of Public Health, University of Washington, Seattle, Wash.
Abstract
OBJECTIVE: The authors examined whether a contingency management intervention using the ethyl glucuronide (EtG) alcohol biomarker resulted in increased alcohol abstinence in outpatients with co-occurring serious mental illnesses. Secondary objectives were to determine whether contingency management was associated with changes in heavy drinking, treatment attendance, drug use, cigarette smoking, psychiatric symptoms, and HIV-risk behavior. METHOD: Seventy-nine (37% female, 44% nonwhite) outpatients with serious mental illness and alcohol dependence receiving treatment as usual completed a 4-week observation period and were randomly assigned to 12 weeks of contingency management for EtG-negative urine samples and addiction treatment attendance, or reinforcement only for study participation. Contingency management included the variable magnitude of reinforcement "prize draw" procedure contingent on EtG-negative samples (<150 ng/mL) three times a week and weekly gift cards for outpatient treatment attendance. Urine EtG, drug test, and self-report outcomes were assessed during the 12-week intervention and 3-month follow-up periods. RESULTS: Contingency management participants were 3.1 times (95% CI=2.2-4.5) more likely to submit an EtG-negative urine test during the 12-week intervention period, attaining nearly 1.5 weeks of additional alcohol abstinence compared with controls. Contingency management participants had significantly lower mean EtG levels, reported less drinking and fewer heavy drinking episodes, and were more likely to submit stimulant-negative urine and smoking-negative breath samples, compared with controls. Differences in self-reported alcohol use were maintained at the 3-month follow-up. CONCLUSIONS: This is the first randomized trial utilizing an accurate and validated biomarker (EtG) to demonstrate the efficacy of contingency management for alcohol dependence in outpatients with serious mental illness.
RCT Entities:
OBJECTIVE: The authors examined whether a contingency management intervention using the ethyl glucuronide (EtG) alcohol biomarker resulted in increased alcohol abstinence in outpatients with co-occurring serious mental illnesses. Secondary objectives were to determine whether contingency management was associated with changes in heavy drinking, treatment attendance, drug use, cigarette smoking, psychiatric symptoms, and HIV-risk behavior. METHOD: Seventy-nine (37% female, 44% nonwhite) outpatients with serious mental illness and alcohol dependence receiving treatment as usual completed a 4-week observation period and were randomly assigned to 12 weeks of contingency management for EtG-negative urine samples and addiction treatment attendance, or reinforcement only for study participation. Contingency management included the variable magnitude of reinforcement "prize draw" procedure contingent on EtG-negative samples (<150 ng/mL) three times a week and weekly gift cards for outpatient treatment attendance. Urine EtG, drug test, and self-report outcomes were assessed during the 12-week intervention and 3-month follow-up periods. RESULTS: Contingency management participants were 3.1 times (95% CI=2.2-4.5) more likely to submit an EtG-negative urine test during the 12-week intervention period, attaining nearly 1.5 weeks of additional alcohol abstinence compared with controls. Contingency management participants had significantly lower mean EtG levels, reported less drinking and fewer heavy drinking episodes, and were more likely to submit stimulant-negative urine and smoking-negative breath samples, compared with controls. Differences in self-reported alcohol use were maintained at the 3-month follow-up. CONCLUSIONS: This is the first randomized trial utilizing an accurate and validated biomarker (EtG) to demonstrate the efficacy of contingency management for alcohol dependence in outpatients with serious mental illness.
Authors: Lois A Benishek; Karen L Dugosh; Kim C Kirby; Jason Matejkowski; Nicolle T Clements; Brittany L Seymour; David S Festinger Journal: Addiction Date: 2014-05-23 Impact factor: 6.526
Authors: Michael G McDonell; Jordan Skalisky; Emily Leickly; Sterling McPherson; Samuel Battalio; Jenny R Nepom; Debra Srebnik; John Roll; Richard K Ries Journal: Drug Alcohol Depend Date: 2015-10-09 Impact factor: 4.492
Authors: August F Holtyn; Mikhail N Koffarnus; Anthony DeFulio; Sigurdur O Sigurdsson; Eric C Strain; Robert P Schwartz; Jeannie-Marie S Leoutsakos; Kenneth Silverman Journal: Prev Med Date: 2014-03-04 Impact factor: 4.018
Authors: Sean M Murphy; Michael G McDonell; Sterling McPherson; Debra Srebnik; Frank Angelo; John M Roll; Richard K Ries Journal: Drug Alcohol Depend Date: 2015-05-14 Impact factor: 4.492
Authors: Mary F Brunette; Dianne Asher; Rob Whitley; Wilma J Lutz; Barbara L Wieder; Amanda M Jones; Gregory J McHugo Journal: Psychiatr Serv Date: 2008-09 Impact factor: 3.084
Authors: Michael G McDonell; Jordan Skalisky; Emily Leickly; Michael F Orr; Sterling McPherson; John Roll; Nathalie Hill-Kapturczak; Martin Javors Journal: Psychol Addict Behav Date: 2017-07-17
Authors: Katherine A Hirchak; Jalene Herron; Sean M Murphy; Dennis Donovan; John M Roll; Dedra Buchwald; Michael G McDonnell; Sterling M McPherson Journal: Am Indian Alsk Native Ment Health Res Date: 2019
Authors: Michael Gerard McDonell; Emily Leickly; Sterling McPherson; Jordan Skalisky; Katherine Hirchak; Oladunni Oluwoye; Debra Srebnik; John Michael Roll; Richard Kirkland Ries Journal: Am J Addict Date: 2017-08-18
Authors: Emily Leickly; Jordan Skalisky; Frank A Angelo; Debra Srebnik; Sterling McPherson; John M Roll; Richard K Ries; Michael G McDonell Journal: Psychiatr Rehabil J Date: 2018-11-26
Authors: Oladunni Oluwoye; Jordan Skalisky; Ekaterina Burduli; Naomi S Chaytor; Sterling McPherson; Sean M Murphy; Jalene Herron; Katherine Hirchak; Mason Burley; Richard K Ries; John M Roll; Michael G McDonell Journal: Contemp Clin Trials Date: 2018-04-20 Impact factor: 2.226
Authors: Ekaterina Burduli; Jordan Skalisky; Katherine Hirchak; Michael F Orr; Albert Foote; Alexandria Granbois; Richard Ries; John M Roll; Dedra Buchwald; Michael G McDonell; Sterling M McPherson Journal: Clin Trials Date: 2018-08-29 Impact factor: 2.486
Authors: Oladunni Oluwoye; Emily Leickly; Jordan Skalisky; Sterling McPherson; Katherine Hirchak; Debra Srebnik; John M Roll; Richard K Ries; Michael G McDonell Journal: Int J Ment Health Addict Date: 2017-10-31 Impact factor: 3.836
Authors: Alexis C Edwards; Henrik Ohlsson; Dace S Svikis; Jan Sundquist; Kristina Sundquist; Kenneth S Kendler Journal: Am J Psychiatry Date: 2018-11-29 Impact factor: 18.112
Authors: Emily Leickly; Jordan Skalisky; Oladunni Oluwoye; Sterling M McPherson; Debra Srebnik; John M Roll; Richard K Ries; Michael G McDonell Journal: Subst Abus Date: 2017-12-08 Impact factor: 3.716